ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2015
Effect of the coffee ingredient cafestol on head and neck squamous cell carcinoma cell lines.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 20 citations in OpenAlex.
- Synergistic Cytotoxicity of Cafestol and Kahweol With Doxorubicin in Breast Cancer Cells Involves TNF‑α Targeting and NF‑κB Downregulation.Archiv der Pharmazie · 2026Article
- Toxicological Risk Assessment of Coffee Oil (Coffee Seed Oil and Spent Coffee Grounds Oil) as a Novel Food with Focus on Cafestol.Molecules (Basel, Switzerland) · 2025Review
- Recent Updates on the Functional Impact of Kahweol and Cafestol on Cancer.Molecules (Basel, Switzerland) · 2022Review
- HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.Wiener klinische Wochenschrift · 2021Article
- Cafestol and Kahweol: A Review on Their Bioactivities and Pharmacological Properties.International journal of molecular sciences · 2019Review
- In vivo protein expression changes in mouse livers treated with dialyzed coffee extract as determined by IP-HPLC.Maxillofacial plastic and reconstructive surgery · 2018Article
- In vitro protein expression changes in RAW 264.7 cells and HUVECs treated with dialyzed coffee extract by immunoprecipitation high performance liquid chromatography.Scientific reports · 2018Article
- Effect of thymoquinone on head and neck squamous cell carcinoma cellsOncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
background and purposeCafestol is a diterpene molecule found in coffee beans and has anticarcinogenic properties. The aim of the study was to examine the effects of cafestol in head and neck squamous cell carcinoma (HNSCC) cells. MATERIALS AND
methodsThree HNSCC cell lines (SCC25, CAL27 and FaDu) were treated with increasing doses of cafestol. Then combination experiments with cisplatin and irradiation were carried out. Drug interactions and possible synergy were calculated using the combination index analysis. Clonogenic assays were performed after irradiation with 2, 4, 6 and 8 Gy, respectively, and the rate of apoptosis was measured with flow cytometry.
resultsTreatment of HNSCC cells with cafestol leads to a dose-dependent reduction of cell viability and to induction of apoptosis. Combination with irradiation shows a reduction of clonogenic survival compared to each treatment method alone. In two of the cell lines a significant additive effect was observed.
conclusionCafestol is a naturally occurring effective compound with growth-inhibiting properties in head and neck cancer cells. Moreover, it leads to a significant inhibition of colony formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.